DBV Soars As Path For Peanut Allergy Patch Approval Clears
Positive FDA Feedback After Earlier Rejection
The French biotech's chances of competing with Aimmune's Palforzia in the peanut allergy market have been boosted after US regulators decided that a fresh Phase III trial for the Viaskin Peanut patch would not be required for resubmission.
